CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. reported that it has discontinued its Phase 2 KOURAGE clinical trial after a recommendation from the study’s Independent Data Monitoring Committee. The company cited reduced planned operating expenses from stopping the trial and updated its cash outlook accordingly.
CalciMedica now expects its existing cash, cash equivalents and short-term investments to fund its current operating plan into the fourth quarter of 2026, an improvement from its prior guidance of funding into the second half of 2026. The company also reiterated standard cautionary language about forward-looking statements and referenced previously disclosed risk factors.
CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure. The move follows a safety-related recommendation from the trial’s Independent Data Monitoring Committee, which believes the study design and patient enrollment criteria should be reevaluated.
The company states there were no deaths assessed as related to Auxora or placebo, and no serious adverse events triggered expedited U.S. Food and Drug Administration reporting. CalciMedica will conduct a comprehensive review of the unblinded data to understand how baseline characteristics, disease severity and concomitant therapies influenced outcomes and to determine how future clinical evaluation of Auxora in AKI may proceed. The FDA has been notified, and investigators will follow all enrolled patients for 90 days.
CalciMedica, Inc. filed its Q3 2025 report, detailing ongoing operating losses and liquidity pressure. The company reported a net loss of $7.804 million for the quarter and $18.802 million for the nine months ended September 30, 2025. Operating expenses were $5.618 million in Q3, led by research and development of $3.851 million.
As of September 30, 2025, cash and cash equivalents were $5.470 million and short‑term investments were $8.614 million. Management states there is substantial doubt about the company’s ability to continue as a going concern. The balance sheet shows a stockholders’ deficit of $268 thousand, a promissory note at fair value of $8.900 million, and a warrant liability of $2.600 million.
The company funded $10.0 million under a loan on February 28, 2025, bearing interest at the greater of 5.00% + prime or 12.75%, maturing on September 1, 2028. During 2025, it raised additional equity via its ATM program, selling 760,130 shares for net proceeds of $1.761 million through September 30. Shares outstanding were 14,409,431 as of November 6, 2025.
CalciMedica, Inc. (CALC) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed under the Exchange Act and is not subject to Section 18 liabilities. It will not be incorporated by reference into other filings except if specifically referenced.
CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000. The company filed a prospectus supplement to raise the maximum aggregate offering price of common stock that may be issued under its at‑the‑market offering agreement with H.C. Wainwright & Co.
The prior limit under the program was $4,450,000, as referenced in an earlier supplement. A legal opinion covering the $9,700,000 of common stock was included as Exhibit 5.1.
CALC filed a prospectus supplement for its at-the-market program, stating it may offer and sell shares of common stock with an aggregate offering price of up to $9,700,000 from time to time through H.C. Wainwright & Co. as sales agent under Form S-3 General Instruction I.B.6.
The filing cites a public float of approximately $36.3 million, based on 14,399,531 shares outstanding and 10,146,506 shares held by non‑affiliates at a $3.58 closing price on September 9, 2025. The company has sold $2.3 million of securities under I.B.6 during the prior 12 months. The stock last traded at $3.03 on November 5, 2025. Pursuant to I.B.6, public primary sales cannot exceed one‑third of the public float in any 12‑month period while float remains below $75.0 million.
CalciMedica, Inc. (CALC) disclosed a director stock option grant on a Form 4. On 10/13/2025, the reporting person received a Director Stock Option (Right to Buy) for 937 shares of common stock at an exercise price of $3.26 per share, coded A for award.
The option has an expiration date of 10/12/2035 and was reported as Direct (D) ownership with 937 derivative securities beneficially owned following the transaction. The filing notes a vesting schedule: beginning October 1, 2025, 1/3 of the shares subject to the option will vest in equal monthly installments. The option was granted at a price of $0 for the derivative security, consistent with standard equity awards.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.
CalciMedica, Inc. reported that Eric W. Roberts, its chief business officer, director, and a ten percent owner, made an open-market purchase of common stock. On September 15, 2025, a Roth IRA account for his benefit bought 3,400 shares at a weighted average price of $2.6779 per share, with trade prices ranging from $2.65 to $2.70. Following this transaction, that Roth IRA held 81,650 common shares. The filing also updates his other direct and indirect common stock positions, including shares held directly and through multiple IRA and Valence Investments SPV entities.
CalciMedica, Inc. director and chief business officer Eric W. Roberts reported an open-market purchase of 5,000 shares of common stock at $3.12 per share. The shares are held indirectly through an FMTC Custodian Roth IRA for his benefit. The filing also updates his direct and other indirect common stock holdings across several custodial and investment entities.